blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1664271

EP1664271 - MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.04.2012
Database last updated on 14.09.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
[2011/39]
Former [2008/25]For all designated states
ISIS PHARMACEUTICALS, INC.
2292 Faraday Avenue
Carlsbad, CA 92008 / US
Former [2006/23]For all designated states
Isis Parmaceuticals, Inc.
2292 Faraday Avenue
Carlsbad, CA 92008 / US
Inventor(s)01 / BHANOT, Sanjay
7965 Paseo Aliso
Carlsbad, CA 92009 / US
02 / DOBIE, Kenneth, W.
703 Stratford Court, Nr. 4
Del Mar, CA 92014 / US
03 / YU, Xing-Xian
12605 El Camino Real
San Diego, CA 92130 / US
 [2006/30]
Former [2006/23]01 / BHANOT, Sanjay
7965 Paseo Aliso
Carlsbad, CA 92009 / US
02 / DOBIE, Kenneth, W.
703 Stratford Court, Nr. 4
Del Mar, CA 92014 / US
03 / YU, Xing-Xian
1260-F El Camino Real
San Diego, CA 92130 / US
Representative(s)Hallybone, Huw George, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2009/51]Hallybone, Huw George, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2007/40]Hallybone, Huw George, et al
Carpmaels and Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2006/23]Chapman, Paul William, et al
Kilburn & Strode, 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date04779444.118.08.2004
[2006/23]
WO2004US24384
Priority number, dateUS2003064380118.08.2003         Original published format: US 643801
[2006/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005019418
Date:03.03.2005
Language:EN
[2005/09]
Type: A2 Application without search report 
No.:EP1664271
Date:07.06.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 03.03.2005 takes the place of the publication of the European patent application.
[2006/23]
Type: B1 Patent specification 
No.:EP1664271
Date:08.06.2011
Language:EN
[2011/23]
Search report(s)International search report - published on:US04.05.2006
(Supplementary) European search report - dispatched on:EP04.07.2008
ClassificationIPC:C12N15/11, C07H21/04
[2008/32]
CPC:
C12N15/1137 (EP,US); A61P1/16 (EP); A61P3/00 (EP);
A61P3/04 (EP); A61P3/06 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P5/48 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07H21/02 (EP,US);
C12N2310/11 (EP,US); C12N2310/14 (EP,US) (-)
Former IPC [2006/26]C07H21/04
Former IPC [2006/23]C12N1/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/23]
Extension statesAL14.03.2006
HR14.03.2006
LT14.03.2006
LV14.03.2006
MK14.03.2006
TitleGerman:MODULATION DER EXPRESSION VON DIACYLGLYCERIN-ACYLTRANSFERASE 2[2006/23]
English:MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION[2006/23]
French:MODULATION DE L'EXPRESSION DE LA DIACYLGLYCEROL ACYLTRANSFERASE 2[2006/23]
Entry into regional phase14.03.2006National basic fee paid 
14.03.2006Search fee paid 
14.03.2006Designation fee(s) paid 
14.03.2006Examination fee paid 
Examination procedure14.03.2006Examination requested  [2006/23]
07.07.2006Amendment by applicant (claims and/or description)
23.10.2008Despatch of a communication from the examining division (Time limit: M06)
01.05.2009Reply to a communication from the examining division
19.07.2010Cancellation of oral proceeding that was planned for 21.07.2010
21.07.2010Date of oral proceedings (cancelled)
17.12.2010Communication of intention to grant the patent
26.04.2011Fee for grant paid
26.04.2011Fee for publishing/printing paid
Divisional application(s)EP10175722.7  / EP2284267
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.10.2008
Opposition(s)09.03.2012No opposition filed within time limit [2012/20]
Fees paidRenewal fee
07.08.2006Renewal fee patent year 03
03.08.2007Renewal fee patent year 04
08.08.2008Renewal fee patent year 05
07.08.2009Renewal fee patent year 06
06.08.2010Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
DK08.06.2011
EE08.06.2011
FI08.06.2011
HU08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
TR08.06.2011
IE18.08.2011
MC31.08.2011
BG08.09.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
[2013/45]
Former [2013/44]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
DK08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
TR08.06.2011
IE18.08.2011
MC31.08.2011
BG08.09.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2013/29]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
DK08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
IE18.08.2011
MC31.08.2011
BG08.09.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/35]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
DK08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
IE18.08.2011
MC31.08.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/31]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
DK08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
MC31.08.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/18]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
MC31.08.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/11]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
EE08.06.2011
FI08.06.2011
PL08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/10]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
EE08.06.2011
FI08.06.2011
RO08.06.2011
SE08.06.2011
SI08.06.2011
SK08.06.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/09]AT08.06.2011
BE08.06.2011
CY08.06.2011
CZ08.06.2011
EE08.06.2011
FI08.06.2011
SE08.06.2011
SI08.06.2011
GR09.09.2011
ES19.09.2011
PT10.10.2011
Former [2012/05]AT08.06.2011
BE08.06.2011
CY08.06.2011
FI08.06.2011
SE08.06.2011
SI08.06.2011
GR09.09.2011
ES19.09.2011
Former [2011/52]AT08.06.2011
CY08.06.2011
FI08.06.2011
SE08.06.2011
SI08.06.2011
GR09.09.2011
ES19.09.2011
Former [2011/50]CY08.06.2011
FI08.06.2011
SE08.06.2011
SI08.06.2011
GR09.09.2011
ES19.09.2011
Former [2011/49]CY08.06.2011
FI08.06.2011
SE08.06.2011
GR09.09.2011
ES19.09.2011
Documents cited:Search[XY]WO02068595  (UNIV CALIFORNIA [US], et al) [X] 1,12-14,20,23 * page 27, paragraph 2 * * page 31, paragraph 2 - page 32, paragraph 3 * * page 35, paragraph 3 * [Y] 21,22;
 [XY]WO03053363  (MILLENNIUM PHARM INC [US]) [X] 1,12-14,20,23 * paragraphs [0108] , [0110] * * paragraph [0112] * * paragraphs [0302] - [0306] * * paragraph [0318] * [Y] 21,22;
 [DY]  - MARTIN P, "38. EIN NEUER ZUGANG ZU 2'-O-ALKYLRIBONUCLEOSIDEN UND EIGENSCHAFTEN DEREN OLIGONUCLEOTIDE", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA. BASEL, CH, (19950101), vol. 78, ISSN 0018-019X, pages 486 - 504, XP000857415 [DY] 21,22 * page 493, paragraph 2 - page 497, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/hlca.19950780219
International search[Y]US5998148  (BENNETT C FRANK [US], et al);
 [X]US6605451  (MARMARO JEFFERY M [US], et al)
ExaminationWO0071164
 WO0175164
 WO0222635
 WO0244321
 WO0250247
 WO03030826
    - CASES S ET AL, "Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M106219200, (20011019), vol. 276, no. 42, ISSN 0021-9258, pages 38870 - 38876, XP002199715

DOI:   http://dx.doi.org/10.1074/jbc.M106219200
    - ELBASHIR S M ET AL, "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB LNKD- DOI:10.1093/EMBOJ/20.23.6877, (20011203), vol. 20, no. 23, ISSN 0261-4189, pages 6877 - 6888, XP002225998

DOI:   http://dx.doi.org/10.1093/emboj/20.23.6877
    - ELBASHIR SAYDA M ET AL, "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/35078107, (20010524), vol. 411, no. 6836, ISSN 0028-0836, pages 494 - 498, XP002206451

DOI:   http://dx.doi.org/10.1038/35078107
    - ELBASHIR SAYDA M ET AL, "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US LNKD- DOI:10.1101/GAD.862301, (20010115), vol. 15, no. 2, ISSN 0890-9369, pages 188 - 200, XP002204651

DOI:   http://dx.doi.org/10.1101/gad.862301
    - NCBI, (20030406), Database accession no. NM_032564
by applicantUS3687808
 US4426330
 US4469863
 US4476301
 US4534899
 WO8804924
 US4837028
 US5023243
 US5034506
 US5177196
 US5188897
 US5214134
 US5264423
 WO9324510
 US5276019
 US5278302
 US5286717
 WO9426764
 US5466677
 US5489677
 US5543152
 US5561225
 US5587361
 US5602240
 US5608046
 US5610289
 WO9713499
 US5625050
 US5677439
 US5719262
 US5770713
 WO9839352
 WO9914226
 US6287860
 WO0168848
 WO0208260
 WO0236743
 US6426220
 US2003027780
 EP1308459
    - BERGE ET AL., "Pharmaceutical Salts", J. OF PHARMA SCI., (1977), vol. 66, pages 1 - 19
    - MURANISHI, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, (1990), vol. 7, page 1
    - EL-HARIRI ET AL., J. PHARM. PHARMACOL., (1992), vol. 44, page 651
    - PAPAHADJOPOULOS ET AL., ANN. N.Y. ACAD. SCI., (1987), vol. 507, page 64
    - GABIZON ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 85, page 6949
    - SUNAMOTO ET AL., BULL. CHEM. SOC. JPN., (1980), vol. 53, page 2778
    - ILLUM ET AL., FEBS LETT., (1984), vol. 167, page 79
    - KLIBANOV ET AL., FEBS LETT., (1990), vol. 268, page 235
    - CHIANG ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 18162 - 18171
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.